- Home
- CAPR vs RFMZ Comparison
CAPR vs RFMZ Comparison
Compare CAPR & RFMZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- RFMZ
- Stock Information
- Founded
- CAPR 2005
- RFMZ 2021
- Country
- CAPR United States
- RFMZ United States
- Employees
- CAPR N/A
- RFMZ N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- RFMZ Trusts Except Educational Religious and Charitable
- Sector
- CAPR Health Care
- RFMZ Finance
- Exchange
- CAPR Nasdaq
- RFMZ Nasdaq
- Market Cap
- CAPR 324.6M
- RFMZ 310.1M
- IPO Year
- CAPR N/A
- RFMZ N/A
- Fundamental
- Price
- CAPR $6.28
- RFMZ $12.54
- Analyst Decision
- CAPR Strong Buy
- RFMZ
- Analyst Count
- CAPR 8
- RFMZ 0
- Target Price
- CAPR $24.75
- RFMZ N/A
- AVG Volume (30 Days)
- CAPR 1.4M
- RFMZ 76.6K
- Earning Date
- CAPR 08-11-2025
- RFMZ 01-01-0001
- Dividend Yield
- CAPR N/A
- RFMZ 7.43%
- EPS Growth
- CAPR N/A
- RFMZ N/A
- EPS
- CAPR N/A
- RFMZ 0.65
- Revenue
- CAPR $13,392,150.00
- RFMZ N/A
- Revenue This Year
- CAPR N/A
- RFMZ N/A
- Revenue Next Year
- CAPR $6,061.53
- RFMZ N/A
- P/E Ratio
- CAPR N/A
- RFMZ $21.49
- Revenue Growth
- CAPR N/A
- RFMZ N/A
- 52 Week Low
- CAPR $3.98
- RFMZ $11.28
- 52 Week High
- CAPR $23.40
- RFMZ $14.57
- Technical
- Relative Strength Index (RSI)
- CAPR 36.33
- RFMZ 44.54
- Support Level
- CAPR $6.17
- RFMZ $12.45
- Resistance Level
- CAPR $7.30
- RFMZ $12.61
- Average True Range (ATR)
- CAPR 0.43
- RFMZ 0.13
- MACD
- CAPR -0.11
- RFMZ -0.02
- Stochastic Oscillator
- CAPR 4.53
- RFMZ 13.24
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About RFMZ RiverNorth Flexible Municipal Income Fund II Inc.
RiverNorth Flex Muni Income Fund II Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.